aβ42

CES1-IN-42 (2,2-Dimethoxy-2-phenylacetophenone) is a photoinitiator that can be used to assist in cancer research.

β-Amyloid (1-42), acetate (human) is a peptide consisting of 42 amino acids that is part of β-Amyloid and is commonly used in Alzheimer's disease modeling.

TAMRA-Amyloid-β (1-42) peptide is a fluorescently labeled peptide. Amyloid-β (1-42) (Aβ42) is a neurotoxic 42-residue protein fragment found in amyloid plaques in postmortem cerebral cortex from patients with Alzheimer's disease. Aggregation of Aβ42 results in the formation of neurotoxic fibrils or globular oligomers. TAMRA-Amyloid-β (1-42) peptide is a labeled form of Aβ42 containing carboxytetramethyl rhodamine (TAMRA), which displays excitation/emission maxima of 543/572 nm, respectively.

Compound AChE-IN-42, also known as Compound 28, is an acetylcholinesterase (AChE) inhibitor with an inhibition constant (K i) of 0.44 μM [1].

ICMT-IN-42 (compound 21) serves as an ICMT inhibitor, demonstrating potency with an IC50 of 0.054 μM [1].

Amyloid β-Protein (3-42), the precursor of Pyr peptide, serves as the foundation of the amyloid template block in Alzheimer's disease when modified to pyroglutamate Aβ (pEAβ) (3-42). This modified form, pEAβ(3-42), hastens the aggregation of Aβ(1-42) although Aβ(1-42) markedly decelerates both the primary and secondary nucleation of pEAβ(3-42) [1].

α-Glucosidase-IN-42 (Compound 26), a 9-O-berberrubine carboxylate derivative, exhibits potent α-glucosidase inhibitory activity with an IC50 value of 1.61 μM and has potential for use in antidiabetic research [1].

Hexapeptide-42 is a bioactive peptide utilized as a cosmetic ingredient [1].

Antiproliferative Agent-42 (Compound 7m), a dihydrodipyrrolo compound, exhibits antiproliferative activity against the Panc-1 cell line, with an IC 50 of 12.54 μM [1].

GIP (3-42), human (Gastric Inhibitory Polypeptide (3-42) (human)) is a peptide that acts as a glucose-dependent proinsulinotropic polypeptide (GIP) receptor antagonist and regulates insulin secretion and the metabolic effects of GIP in vivo, which can be used to study type 2 diabetes.

FITC-β-Ala-Amyloid β-Protein (1-42) ammonium, a fluorescein isothiocyanate (FITC)-tagged monomer peptide of Aβ1-42, is instrumental in Alzheimer’s disease pathogenesis [1].

[Arg6]-β-Amyloid (1-42), England mutation, is a biologically active peptide associated with autosomal dominant Alzheimer's Disease in various kindreds. The English (H6R) mutation disrupts H6 interactions due to several mutations in the beta-amyloid precursor gene.

GIP (3-42), human acetate is an antagonist of a glucose-dependent insulinotropic polypeptide (GIP) receptor and regulates insulin secretion and GIP metabolism in vivo.

[Asn23]-beta-Amyloid (1-42), Iowa mutation, is a biologically active peptide exhibiting increased aggregation propensity and fibril toxicity. This mutation involves the substitution of Aspartic acid (Asp) at position 23 with Asparagine (Asn), contributing to autosomal dominant Alzheimer's Disease in various kindreds due to its association with severe cerebral amyloid beta-protein angiopathy (CAA). Specifically, the mutation is a missense alteration at position 694 of the amyloid precursor protein (APP) gene.

Anti-inflammatory agent 42 has anti-inflammatory activity and inhibits the expression of TNF-α and IL-6 in LPS-stimulated macrophages.

Aβ42-IN-2 is a γ-secretase modulator. Aβ42-IN-2 has an IC 50 of 6.5 nM for Αβ 42. Aβ42-IN-2 can be used for the Alzheimer's disease research[1].

(Met(O)35)-Amyloid β-Protein (1-42) represents the oxidized form of Methionine 35 in Aβ42, capable of producing an oligomer size distribution akin to that of Aβ40. This compound is utilized in Alzheimer’s disease (AD) research [1].

Biotin-amyloid-β (1-42) peptide is an affinity probe that allows amyloid-β (1-42) (Aβ42) to be detected or immobilized through interaction with the biotin ligand. It has been used to identify Aβ42 interaction partners in rat hippocampal synaptosomal membranes.

(Glu20)-Amyloid β-Protein (1-42) represents a variant of amyloid β-protein (Aβ) that fibrillizes more slowly. This is attributed to the Glu20 mutation, which diminishes Aβ42's tendency to aggregate and inhibits the accumulation of this slowly fibrillizing peptide. Notably, amyloid β-protein serves as the principal constituent of amyloid deposits found in both the vascular system and brain parenchyma in Alzheimer's disease [1] [2].

Amyloid-β (1-42) (Aβ42) is a neurotoxic 42-amino acid protein fragment found in amyloid plaques in postmortem cerebral cortex from patients with Alzheimer's disease.1,2,3Aggregation of Aβ42 results in the formation of neurotoxic fibrils or globular oligomers.1Aβ42 accumulates in the brain of many transgenic mouse models of Alzheimer's disease and, in many models, the onset of amyloid deposition positively correlates with deficits in spatial learning and memory.4 1.Wolfe, M.S.Therapeutic strategies for Alzheimer's diseaseNat. Rev. Drug Discov.1(11)859-866(2002) 2.Iwatsubo, T., Odaka, A., Suzuki, N., et al.Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43)Neuron13(1)45-53(1994) 3.Hardy, J.A., and Higgins, G.A.Alzheimer's disease: The amyloid cascade hypothesisScience256(5054)184-185(1992) 4.Jankowsky, J.L., and Zheng, H.Practical considerations for choosing a mouse model of Alzheimer's diseaseMol. Neurodegener.12(1)89(2017)

Amyloid β-Protein (33-42) TFA, a fragment encompassing residues 33-42 of the β-amyloid protein, mitigates the toxicity induced by Aβ42 [1].

Antibacterial Agent 42 demonstrates potent antibacterial activity by effectively reducing the Minimum Inhibitory Concentration (MIC) of the broad-spectrum antibacterial agent Ceftazidime.

Maximin 42 is an antimicrobial peptide with antibacterial activity against S. aureus (MIC: 37.5 μg/mL) and exhibits hemolytic activities against human red cells [1].

Biotinyl-Ahx-Amyloid β-Protein (1-42) ammonium is an N-terminally biotin-tagged form of Amyloid β-Protein (1-42), which constitutes the main component of vascular and parenchymal amyloid deposits associated with Alzheimer's disease [1].

(Met(O2)35)-Amyloid β-Protein (1-42) is a peptide [1] .

(Gln22)-Amyloid β-Protein (1-42), a Dutch mutation (E22Q) variant of β-Amyloid (1-42), demonstrates increased fibrillogenic and pathogenic characteristics [1].

Tubulin polymerization-IN-42 (compound 10j), an indole-substituted furanone, inhibits tubulin polymerization and exhibits anti-cancer properties [1].

HDAC-IN-42 (compound 14f) is a highly potent and selective inhibitor of histone deacetylase (HDAC) enzymes, with IC50 values of 0.19 μM for HDAC1 and 4.98 μM for HDAC6. It exhibits remarkable anticancer properties and inhibits cell proliferation. Additionally, HDAC-IN-42 induces apoptosis and causes cell cycle arrest specifically at the G2/M phase [1].

(D-Asp1)-Amyloid β-Protein (1-42), a peptide fragment of amyloid β-protein (Aβ), serves as the primary constituent of vascular and parenchymal amyloid deposits associated with Alzheimer's disease [1].

[Tyr0] Gastric Inhibitory Peptide (23-42), human, functions as a glucose-dependent insulinotropic polypeptide (GIP) and exhibits dual activity: it modestly inhibits gastric acid secretion while simultaneously enhancing insulin secretion. This characteristic makes it applicable in research related to diabetes and obesity [1] [2].

HIV-1 inhibitor-42 (compound 5b) is a potent inhibitor of HIV-1 (IC50: 0.06 μM). HIV-1 inhibitor-42 inhibits HIV-1 RT RNA-dependent DNA polymerase (IC50: 0.518 μM) and DNA-dependent DNA polymerase (IC50. 0.072 μM).

SARS-CoV-2-IN-42 (Compound 8q) effectively inhibits SARS-CoV-2 replication with an EC50 value of 0.4 μM and demonstrates no significant toxicity to the host cell [1].

Gastric inhibitory peptide (GIP) (1-42), an endogenous incretin hormone comprising 42 amino acids, promotes insulin secretion. Expressed in the intestinal neuroendocrine K cells and submandibular gland, it enters circulation after meals. GIP (1-42) blocks histamine, pentagastrin, and insulin-induced gastric acid and pepsin secretion, enhances glucose-stimulated insulin release, and accelerates gastric emptying in rats.

AK-42 is a novel potent and specific inhibitor of CLC-2, displaying unprecedented selectivity over CLC-1, the closest CLC-2 homolog, and exhibiting no off-target engagement against a panel of 61 common channels, receptors, and transporters expressed in brain tissue.

β-Amyloid (42-1), human TFA, a 42-amino acid peptide, represents the inactive form of Amyloid β Peptide (1-42) and is pivotal in the development of Alzheimer's disease [1].

(Gly22)-Amyloid β-Protein (1-42), a peptide fragment of Amyloid β-Protein (Aβ), plays a crucial role in Alzheimer's disease by forming the main component of both vascular and parenchymal amyloid deposits. The mutation from Glu22 to Gly22 in Aβ is known to enhance aggregation [1] [2].

'(Lys22)-Amyloid β-Protein (1-42) represents a mutation of the wild-type (WT) Amyloid β-Protein (1-42) peptide [1].'

Anticancer agent 42 (compound 10d) is an orally active, potent anticancer agent with demonstrated efficacy against MDA-MB-231 cells, exhibiting an IC50 of 0.07 μM. It exerts its anticancer activity through the activation of apoptotic pathways and p53 expression. Anticancer agent 42 is a valuable tool for investigating metastatic breast cancer [1].

Antifungal agent 42 is an antifungal agent that has an inhibitory effect on biofilm formation. Antifungal agent 42 inhibits C.alb.'s lanosterol 14α-demethylase (CYP51).

Aβ1-42 aggregation inhibitor 1 effectively inhibits acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), demonstrating IC50 values of 2.64 μM and 1.29 μM, respectively. At a concentration of 25 μM, it also reduces self-mediated Aβ1-42 aggregation by 51.29%, showcasing its potential for Alzheimer's disease research [1].

p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb #4695R is a useful organic compound for research related to life sciences and the catalog number is T64587.

Antitumor agent-42 inhibits microtubule multimerisation and NO release, exhibiting anti-angiogenic, colony-forming and apoptosis-inducing effects.

EGFR-IN-42 (Compound 17b), a potent EGFR inhibitor, demonstrates single-digit nanomolar activity by covalently linking tamoxifen or endoxifen with gefitinib, retaining both ER antagonist activity and EGFR inhibition, resulting in superior anti-cancer activity [1].

Amyloid 17-42 (Aβ(17-42)), a significant component of diffuse plaques in Alzheimer's disease and cerebellar pre-amyloid in Down's syndrome, results from the alpha- and gamma-secretase cleavage of amyloid precursor protein (APP). It has the capability to trigger neuronal apoptosis through the Fas-like/caspase-8 activation pathway [1].

Biotinyl-Amyloid β-Protein (1-42) ammonium, a biotinylated variant of Amyloid β-Protein (1-42), is utilized in research focused on the conversion of Aβ1-42 to Aβ1-40 in the brain [1].

Amyloid β-Protein (36-42), the 36-42 fragment of β-Amyloid, consists of a polypeptide chain of 36-43 amino acids and is a primary constituent of amyloid plaques in Alzheimer's disease (AD) patients' brains. β-Amyloid oligomers (Aβos) critically contribute to AD progression by causing neuronal harm and cognitive decline [1].

'(Asp37)-Amyloid β-Protein (1-42) [1]' refers to the G37D mutant variant of the wild-type Amyloid-beta (1-42) peptide.

ChE/Aβ1-42-IN-1 (compound 28) is a potent aggregation inhibitor of ChE and Aβ 1-42 with excellent BBB permeability. The IC50 values of ChE/Aβ1-42-IN-1 for AChE, BuChE and Aβ 1-42 aggregation are 0.062, 0.767 and 1.227 μM, respectively. ChE/Aβ1-42-IN-1 is a potent multi-targeted anti-Alzheimer's disease agent [1].

NI-42 is a structurally orthogonal chemical probe for the BRPFs and is biased. It effective inhibitor of the BRD of the BRPFs (IC50s of BRPF1/2/3=7.9/48/260 nM; Kds of BRPF1/2/3=40/210/940 nM). It also has excellent selectivity over nonclass IV BRD protei

β-Amyloid (1-42), (rat mouse) (TFA) is a peptide fragment consisting of 42 amino acids that can be used to study Alzheimer's disease.